Aclaris Therapeutics, Inc. (ACRS) vs Phathom Pharmaceuticals, Inc. (PHAT)

Aclaris Therapeutics, Inc. and Phathom Pharmaceuticals, Inc. are both Biotechnology companies. Aclaris Therapeutics, Inc. and Phathom Pharmaceuticals, Inc. are of similar size ($589.0M and $572.8M). Phathom Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 110.2% against −51.0%. Phathom Pharmaceuticals, Inc. has the higher net margin (−41.3% vs −921.5%) and the higher return on invested capital (0.00% vs −163.4%). Across the 16 metrics below, Phathom Pharmaceuticals, Inc. leads on 13 and Aclaris Therapeutics, Inc. on 3.

Valuation

Metric ACRS PHAT Biotechnology median
P/E n/m n/m 7.88
P/S 89.44 2.55 11.47
P/B 5.90 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 78.52 2.49 10.73
Earnings yield (11.26%) (17.51%) (28.84%)
Free cash flow yield (8.46%) (6.03%) (23.03%)

Profitability

Metric ACRS PHAT Biotechnology median
Gross margin 12.90% 82.92% 65.16%
Operating margin (1,050.16%) (16.96%) 0.00%
Net margin (921.50%) (41.34%) 0.00%
Free cash flow margin (756.50%) (15.40%) 0.00%
Return on equity (59.10%) 26.42% (57.72%)
Return on assets (41.07%) (34.32%) (49.22%)
Return on invested capital (163.35%) 0.00% 0.00%

Growth

Metric ACRS PHAT Biotechnology median
Revenue growth (TTM) (51.04%) 110.16% 5.64%
EPS growth (last fiscal year) 69.01% 42.72% —
Revenue growth, 5-year CAGR 3.84% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACRS PHAT Biotechnology median
Debt to equity 0.00 (0.48) 0.00
Current ratio 3.46 1.92 4.73
Net debt to EBITDA 1.20 (0.51) 0.96

Dividend

Metric ACRS PHAT Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ACRS PHAT Biotechnology median
Market cap 588.97m 572.78m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack